Jupiter Topco LLC Purchases Shares of 4,352,448 Tyra Biosciences, Inc. $TYRA

Jupiter Topco LLC acquired a new position in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) in the second quarter, Holdings Channel.com reports. The institutional investor acquired 4,352,448 shares of the company’s stock, valued at approximately $139,161,000. Jupiter Topco LLC owned 0.07% of Tyra Biosciences as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of TYRA. Millennium Management LLC lifted its holdings in shares of Tyra Biosciences by 28.2% in the first quarter. Millennium Management LLC now owns 404,165 shares of the company’s stock valued at $3,759,000 after purchasing an additional 89,024 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in Tyra Biosciences by 21.7% during the first quarter. Goldman Sachs Group Inc. now owns 78,006 shares of the company’s stock worth $725,000 after buying an additional 13,896 shares in the last quarter. Woodline Partners LP purchased a new stake in Tyra Biosciences in the 1st quarter valued at $931,000. Jane Street Group LLC purchased a new stake in Tyra Biosciences in the 1st quarter valued at $324,000. Finally, Geode Capital Management LLC lifted its stake in Tyra Biosciences by 9.8% during the 2nd quarter. Geode Capital Management LLC now owns 567,126 shares of the company’s stock valued at $5,428,000 after acquiring an additional 50,836 shares in the last quarter. 84.14% of the stock is owned by hedge funds and other institutional investors.

Tyra Biosciences Trading Down 1.8%

TYRA stock opened at $26.22 on Thursday. The stock has a market cap of $1.56 billion, a P/E ratio of -10.93 and a beta of 0.77. The stock’s fifty day simple moving average is $29.62 and its two-hundred day simple moving average is $32.25. Tyra Biosciences, Inc. has a 1-year low of $11.70 and a 1-year high of $40.65.

Tyra Biosciences (NASDAQ:TYRA) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04). As a group, analysts forecast that Tyra Biosciences, Inc. will post -2.74 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have issued reports on TYRA. JonesTrading assumed coverage on shares of Tyra Biosciences in a report on Wednesday, June 17th. They set a “buy” rating and a $56.00 price objective on the stock. Bank of America increased their target price on shares of Tyra Biosciences from $37.00 to $42.00 and gave the company a “buy” rating in a report on Wednesday, June 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Tyra Biosciences in a research report on Friday, July 17th. HC Wainwright restated a “buy” rating and set a $45.00 price target on shares of Tyra Biosciences in a report on Thursday, May 14th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $42.00 price objective on shares of Tyra Biosciences in a research report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $46.90.

Tyra Biosciences Company Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.